The role of Tau protein in resistance to paclitaxel - Archive ouverte HAL Access content directly
Journal Articles Cancer Chemotherapy and Pharmacology Year : 2011

The role of Tau protein in resistance to paclitaxel

Abstract

Resistance to taxanes, related to limited efficacy of systemic therapy in cancer patients, is multifactorial. Among mechanisms of resistance to taxanes, those related to microtubule-associated proteins (MAP), including protein Tau, are of great importance. Protein Tau (50-64 kD) binds to beta-tubulin in the same place as paclitaxel. In preclinical studies, low expression of Tau in cancer cells was associated with increased sensitivity to paclitaxel. High expression of Tau protein in ER-positive breast cancers indicates resistance to taxane-containing chemotherapy and sensitivity to hormonal treatment. This article reviews current knowledge on predictive value of protein Tau in response to taxanes. Better understanding of its role may facilitate patients selection to this sort of treatment and lead to treatment optimization.

Domains

Cancer
Fichier principal
Vignette du fichier
PEER_stage2_10.1007%2Fs00280-011-1696-7.pdf (142.93 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-00713061 , version 1 (29-06-2012)

Identifiers

Cite

Marta Smoter, Lubomir Bodnar, Renata Duchnowska, Rafał Stec, Bartłomiej Grala, et al.. The role of Tau protein in resistance to paclitaxel. Cancer Chemotherapy and Pharmacology, 2011, 68 (3), pp.553-557. ⟨10.1007/s00280-011-1696-7⟩. ⟨hal-00713061⟩

Collections

PEER
47 View
68 Download

Altmetric

Share

Gmail Facebook X LinkedIn More